An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found.
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
PSMA PET scans significantly enhance detection and staging of prostate cancer, improving patient stratification and survival outcomes. Three FDA-approved PSMA PET scans are available, aiding in both ...
Positron emission tomography (PET) is a type of imaging scan that doctors might use when diagnosing and treating non-Hodgkin’s lymphoma (NHL). It can be useful for identifying and staging the cancer.
Medicare Part B covers outpatient PET scans when ordered by a doctor and considered medically necessary. PET scan costs can vary depending on whether you have the scan in a hospital as an inpatient, ...
Dr. Mathieu Spriet is an Associate Professor of Diagnostic Imaging at the School of Veterinary Medicine at the University of California-Davis. In 2015, the Grayson-Jockey Club Research Foundation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results